Neurocrine received approval from the FDA this week to begin commercialization of Ingrezza, currently the only FDA-approved treatment of tardive dyskinesia. The drug will help combat involuntary motions caused by the disease. As of the approval, Ingrezza is the first certified therapy to enter the tardive dyskinesia market. Teva’s Austedo is hoping for the same approval later this year. Read the full article here.